Health ❯ Healthcare ❯ Patient Outcomes

Survival Rates

Progression-Free Survival Treatment Efficacy Event-Free Survival Overall Survival Cancer Prognosis Radiographic Progression-Free Survival Disease-Free Survival Adverse Events Cancer Survival Rates Long-term Survival

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

The company plans regulatory discussions following the rPFS win.

Laser-Guided Tumor Ablation Plus Pembrolizumab More Than Doubles Survival in Recurrent Astrocytoma Trial

Treating Advanced Lung Cancer Before 3 p.m. Extends Survival in Phase III Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

FDA Approves Zycubo, First U.S. Treatment for Menkes Disease

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Large U.S. Study Links IV Iron to Better Survival in Acute Infections With Iron-Deficiency Anemia

Largest Sickle Cell Transplant Analysis Finds Durable Survival and Disease Control

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Channel 4’s Cancer Detectives Concludes Thursday With Focus on Blood Tests to Spot Cancer Early

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

mRNA Covid Vaccination Linked to Longer Survival When Given Near Cancer Immunotherapy, Nature Study Finds

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma